ESPRIT in context: Pharmacology matters!

European Heart Journal

Volumn 22, Issue 21, 2001, Pages 1965-1967

  Tcheng, J E ^a   Strony, J ^b   Lorenz, T J ^c   O'Shea, J C ^a  

^a DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^b MERCK RESEARCH LABORATORIES   (United States)

^c MILLENNIUM PHARMACEUTICALS INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; ANTITHROMBOCYTIC AGENT; EPTIFIBATIDE; FIBRINOGEN RECEPTOR; FIBRINOGEN RECEPTOR ANTAGONIST; TIROFIBAN;

CLINICAL TRIAL; CROSSOVER PROCEDURE; DRUG COST; DRUG EFFICACY; DRUG HALF LIFE; DRUG RECEPTOR BINDING; EDITORIAL; HEART MUSCLE ISCHEMIA; HIGH RISK PATIENT; HUMAN; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS; THROMBOSIS;

ANGIOPLASTY; ANTIBODIES, MONOCLONAL; HALF-LIFE; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; PEPTIDES; PLATELET AGGREGATION INHIBITORS; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; TYROSINE;

EID: 0035178024     PISSN: 0195668X     EISSN: None     Source Type: Journal    
DOI: 10.1053/euhj.2001.2682     Document Type: Editorial

References (15)

1. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. The EPIC Investigation
2. Platelet glycoprotein Iib/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization
3. Randomised placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: The CAPTURE Study
4. Randomised placebo-controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention: IMPACT-II Integrilin to Minimise Platelet Aggregation and Coronary Thrombosis-II
5. Effects of platelet glycoprotein IIb/IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty. Randomized Efficacy Study of Tirofiban for Outcomes and Restenosis
6. Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes. Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy
7. A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina. Platelet Receptor Inhibition in Ischemic Syndrome Management (PRISM)
8. Clinical outcomes of therapeutic agents that block the platelet glycoprotein IIb/IIIa integrin in ischemic heart disease
9. Glycoprotein IIb/IIIa integrin blockade
10. Novel dosing regimen of eptifibatide in planned coronary stent implantation (ESPRIT): A randomised, placebo-controlled trial. Enhanced Suppression of the Platelet IIb/IIIa Receptor with Integrilin Therapy
11. Effect of Ca2+ on GP IIb-IIIa interactions with integrilin: Enhanced GP Iib-IIIa binding and inhibition of platelet aggregation by reductions in the concentration of ionized calcium in plasma anticoagulated with citrate
12. Pharmacodynamics of chimeric glycoprotein IIb/IIIa integrin antiplatelet antibody Fab 7E3 in high-risk coronary angioplasty
13. Platelet glycoprotein llb/IIIa receptor blockade with highdose IntegrilinTM in coronary intervention. Results of the PRIDE study
14. Eptifibatide improves coronary flow reserve following stent placement: An ESPRIT substudy
15. Predictors of improvement in clinical outcomes of non-acute coronary stenting in the ESPRIT trial